Latest Pharmacy News

Emyria Limited is on track to open its first Empax clinic in Victoria by Q2 2026, having secured key operational milestones including a trained clinical workforce and dual reimbursement pathways.

Vitura Health has inked a binding distribution agreement with MedReleaf Australia, unlocking access to a broad medicinal cannabis portfolio across its extensive pharmacy network. This deal could add up to AUD 15 million annually, positioning Vitura as a dominant player in the evolving Australian market.

Bio-Gene has signed a term sheet with Sumitomo Corporation and Nakashima Trading to introduce its 100% natural insecticide Qcide® to Japan’s $1 billion household pest market, aiming for a late 2026 launch.

Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.

Epsilon Healthcare Limited has reported a robust recovery in 2025, with revenue climbing 68% to $9.39 million and net losses shrinking by 63%, driven by growth in contract manufacturing and a new pharmacy division.

Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.

Pharmx Technologies reported a 3.1% revenue increase to $3.89 million for H1 FY26 but posted a net loss of $512,000 driven by strategic investments. The company also announced a significant multi-year alliance with Sigma Healthcare.

Nuchev Limited reported a 12% increase in revenue to $12.38 million for the half-year ended December 2025, driven by growth in core products and offshore markets. However, the company’s net loss widened to $2.34 million amid ongoing investments in marketing, product development, and international expansion.

Pharmx Technologies has entered a multi-year strategic alliance with Sigma Healthcare, becoming the preferred EDI provider for Sigma and Chemist Warehouse across Australia and New Zealand, while Sigma takes a significant equity stake.

Biome Australia Limited has reported a robust half-year performance, with revenues climbing nearly 40% and net profit more than doubling, driven by strong product momentum and strategic investments.

McPherson’s Limited has confirmed a $3.3 million total tax benefit following amended assessments by the ATO, linked to deductible costs from a strategic alliance announced in 2022.

Wesfarmers has reported a 9.3% rise in net profit after tax to $1.6 billion for H1 2026, driven by robust performances in Bunnings, Kmart Group, and lithium operations. The company also announced a 7.4% increase in its interim dividend amid ongoing cost pressures and strategic AI partnerships.